Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.

Beigel JH, Aga E, Elie-Turenne MC, Cho J, Tebas P, Clark CL, Metcalf JP, Ozment C, Raviprakash K, Beeler J, Holley HP Jr, Warner S, Chorley C, Lane HC, Hughes MD, Davey RT Jr; IRC005 Study Team.

Lancet Respir Med. 2019 Sep 30. pii: S2213-2600(19)30199-7. doi: 10.1016/S2213-2600(19)30199-7. [Epub ahead of print]

PMID:
31582360
2.

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.

Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, Khurana S, Engen N, Gordin F, Jain MK, Kan V, Polizzotto MN, Riska P, Ruxrungtham K, Temesgen Z, Lundgren J, Beigel JH, Lane HC, Neaton JD; INSIGHT FLU-IVIG Study Group.

Lancet Respir Med. 2019 Sep 30. pii: S2213-2600(19)30253-X. doi: 10.1016/S2213-2600(19)30253-X. [Epub ahead of print]

3.

Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial.

Beigel JH, Manosuthi W, Beeler J, Bao Y, Hoppers M, Ruxrungtham K, Beasley RL, Ison M, Avihingsanon A, Losso MH, Langlois N, Hoopes J, Lane HC, Holley HP, Myers CA, Hughes MD, Davey RT.

Clin Infect Dis. 2019 Jul 27. pii: ciz634. doi: 10.1093/cid/ciz634. [Epub ahead of print]

PMID:
31541242
4.

New filovirus disease classification and nomenclature.

Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA 2nd, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM 3rd, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O'Dempsey T, Pawęska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z.

Nat Rev Microbiol. 2019 May;17(5):261-263. doi: 10.1038/s41579-019-0187-4. No abstract available.

5.

The Special Pathogens Research Network: Enabling Research Readiness.

Kraft CS, Kortepeter MG, Gordon B, Sauer LM, Shenoy ES, Eiras DP, Larson L, Garland JA, Mehta AK, Barrett K, Price CS, Croyle C, West LR, Noren B, Kline S, Arguinchona C, Arguinchona H, Grein JD, Connally C, McLellan S, Risi GF, Uyeki TM, Davey RT Jr, Schweinle JE, Schwedhelm MM, Harvey M, Hunt RC, Kratochvil CJ.

Health Secur. 2019 Jan/Feb;17(1):35-45. doi: 10.1089/hs.2018.0106.

6.

Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines.

Bhadelia N, Sauer L, Cieslak TJ, Davey RT, McLellan S, Uyeki TM, Kortepeter MG; National Ebola Training and Education Center's Special Pathogens Research Network (SPRN)'s Medical Countermeasures Working Group.

Health Secur. 2019 Jan/Feb;17(1):46-53. doi: 10.1089/hs.2018.0092. Epub 2019 Feb 6.

7.

The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

Davey RT Jr, Dodd L, Proschan M, Jahrling P, Hensley L, Higgs E, Lane HC.

J Infect Dis. 2018 Nov 22;218(suppl_5):S690-S697. doi: 10.1093/infdis/jiy334.

PMID:
30032267
8.

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.

Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, Davey RT Jr.

Lancet Infect Dis. 2018 Apr;18(4):410-418. doi: 10.1016/S1473-3099(18)30002-1. Epub 2018 Jan 9.

9.

Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.

Pett SL, Kunisaki KM, Wentworth D, Griffin TJ, Kalomenidis I, Nahra R, Montejano Sanchez R, Hodgson SW, Ruxrungtham K, Dwyer D, Davey RT, Wendt CH; INSIGHT FLU003 Plus Study Group .

Open Forum Infect Dis. 2017 Oct 25;5(1):ofx228. doi: 10.1093/ofid/ofx228. eCollection 2018 Jan.

10.

Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015.

Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Wentworth D, Uyeki TM, Gordin F, Angus B, Qvist T, Emery S, Lundgren J, Neaton JD; INSIGHT Influenza Study Group .

Open Forum Infect Dis. 2017 Oct 7;4(4):ofx212. doi: 10.1093/ofid/ofx212. eCollection 2017 Fall.

11.

Ebola virus disease: an update on post-exposure prophylaxis.

Fischer WA 2nd, Vetter P, Bausch DG, Burgess T, Davey RT Jr, Fowler R, Hayden FG, Jahrling PB, Kalil AC, Mayers DL, Mehta AK, Uyeki TM, Jacobs M.

Lancet Infect Dis. 2018 Jun;18(6):e183-e192. doi: 10.1016/S1473-3099(17)30677-1. Epub 2017 Nov 15. Review.

12.

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.

Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team.

Lancet Infect Dis. 2017 Dec;17(12):1255-1265. doi: 10.1016/S1473-3099(17)30476-0. Epub 2017 Sep 22.

13.

Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation.

Beigel JH, Voell J, Muñoz P, Kumar P, Brooks KM, Zhang J, Iversen P, Heald A, Wong M, Davey RT.

Br J Clin Pharmacol. 2018 Jan;84(1):25-34. doi: 10.1111/bcp.13405. Epub 2017 Sep 22.

14.

Evidence of Ebola Virus Replication and High Concentration in Semen of a Patient During Recovery.

Barnes KG, Kindrachuk J, Lin AE, Wohl S, Qu J, Tostenson SD, Dorman WR, Busby M, Siddle KJ, Luo CY, Matranga CB, Davey RT, Sabeti PC, Chertow DS.

Clin Infect Dis. 2017 Oct 15;65(8):1400-1403. doi: 10.1093/cid/cix518.

15.

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.

Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns CB, Shoham S, Deville JG, Feucht E, Feinberg J, Luke T, Raviprakash K, Danko J, O'Neil D, Metcalf JA, King K, Burgess TH, Aga E, Lane HC, Hughes MD, Davey RT; IRC002 Study Team.

Lancet Respir Med. 2017 Jun;5(6):500-511. doi: 10.1016/S2213-2600(17)30174-1. Epub 2017 May 15. Erratum in: Lancet Respir Med. 2017 Jul;5(7):e26.

16.

Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Kash JC, Walters KA, Kindrachuk J, Baxter D, Scherler K, Janosko KB, Adams RD, Herbert AS, James RM, Stonier SW, Memoli MJ, Dye JM, Davey RT Jr, Chertow DS, Taubenberger JK.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaai9321. doi: 10.1126/scitranslmed.aai9321.

17.

Trial of ZMapp for Ebola Virus Infection.

Davey RT Jr, Nordwall J, Proschan MA; Prevail II Study Team.

N Engl J Med. 2017 Feb 16;376(7):700-701. doi: 10.1056/NEJMc1614625. No abstract available.

PMID:
28199801
18.

Pneumocystis colonization in asthmatic patients not receiving oral corticosteroid therapy.

Davey EL, Colombo RE, Fiorentino C, Fahle G, Davey RT Jr, Olivier KN, Kovacs JA.

J Investig Med. 2017 Apr;65(4):800-802. doi: 10.1136/jim-2016-000381. Epub 2017 Feb 13.

19.

Corrigendum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT Jr, Beigel JH.

Nat Med. 2017 Feb 7;23(2):264. doi: 10.1038/nm0217-264c. No abstract available.

PMID:
28170379
20.

Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT Jr, Beigel JH.

Nat Med. 2016 Dec;22(12):1439-1447. doi: 10.1038/nm.4201. Epub 2016 Oct 31. Erratum in: Nat Med. 2017 Feb 7;23 (2):264.

PMID:
27798615
21.

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

PREVAIL II Writing Group; Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D.

N Engl J Med. 2016 Oct 13;375(15):1448-1456.

22.

Cardiac MRI Findings Suggest Myocarditis in Severe Ebola Virus Disease.

Chertow DS, Childs RW, Arai AE, Davey RT Jr.

JACC Cardiovasc Imaging. 2017 Jun;10(6):711-713. doi: 10.1016/j.jcmg.2016.06.004. Epub 2016 Aug 17. No abstract available.

23.

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.

Wong KK, Davey RT Jr, Hewlett AL, Kraft CS, Mehta AK, Mulligan MJ, Beck A, Dorman W, Kratochvil CJ, Lai L, Palmore TN, Rogers S, Smith PW, Suffredini AF, Wolcott M, Ströher U, Uyeki TM.

Clin Infect Dis. 2016 Aug 1;63(3):376-9. doi: 10.1093/cid/ciw256. Epub 2016 Apr 26.

24.

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT Jr, Taubenberger JK.

MBio. 2016 Apr 19;7(2):e00417-16. doi: 10.1128/mBio.00417-16.

25.

Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report.

Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS, Bishop RJ, Childs RW, Arai AE, Palmore TN, Lane HC, Fauci AS, Davey RT.

Ann Intern Med. 2016 Aug 16;165(4):301-4. doi: 10.7326/M15-3066. Epub 2016 Apr 5. No abstract available.

26.

Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study.

Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT Jr.

J Infect Dis. 2016 Jun 15;213(12):1906-13. doi: 10.1093/infdis/jiw061. Epub 2016 Feb 11.

27.

Clinical Management of Ebola Virus Disease in the United States and Europe.

Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J; Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe.

N Engl J Med. 2016 Feb 18;374(7):636-46. doi: 10.1056/NEJMoa1504874.

28.

A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma.

Colombo RE, Fiorentino C, Dodd LE, Hunsberger S, Haney C, Barrett K, Nabha L, Davey RT Jr, Olivier KN.

BMC Infect Dis. 2016 Feb 1;16:54. doi: 10.1186/s12879-016-1358-9.

29.

Response.

Torabi-Parizi P, Davey RT Jr, Suffredini AF, Chertow DS.

Chest. 2015 Aug;148(2):e65. doi: 10.1378/chest.15-0986. No abstract available.

30.

Challenges in managing patients who have suspected or confirmed Ebola virus infection at the National Institutes of Health.

Palmore TN, Barrett K, Michelin A, Ramsburg A, Lee LM, Davey RT, Henderson DK.

Infect Control Hosp Epidemiol. 2015 Jun;36(6):623-6. doi: 10.1017/ice.2015.60. No abstract available.

31.

Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States.

Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, Barrett K, Wolcott MJ, Marconi VC, Lyon GM 3rd, Weinstein GL, Weinmeister K, Sutton S, Hazbun M, Albariño CG, Reed Z, Cannon D, Ströher U, Feldman M, Ribner BS, Lane HC, Fauci AS, Uyeki TM.

Ann Intern Med. 2015 Jul 21;163(2):81-90. doi: 10.7326/M15-0530.

32.

State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus.

Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S84-90. doi: 10.1093/infdis/jiv115. Epub 2015 May 9.

33.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

34.

Ethical and practical considerations in providing critical care to patients with Ebola virus disease.

Torabi-Parizi P, Davey RT Jr, Suffredini AF, Chertow DS.

Chest. 2015 Jun;147(6):1460-1466. doi: 10.1378/chest.15-0278.

35.

Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.

Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M, Dunfee RL, Shaw PA, Davey RT, Taubenberger JK.

Clin Infect Dis. 2015 Mar 1;60(5):693-702. doi: 10.1093/cid/ciu924. Epub 2014 Nov 20.

36.

Preparing for critical care services to patients with Ebola.

Decker BK, Sevransky JE, Barrett K, Davey RT, Chertow DS.

Ann Intern Med. 2014 Dec 2;161(11):831-2. doi: 10.7326/M14-2141. No abstract available.

PMID:
25244048
37.

Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.

Borges ÁH, Weitz JI, Collins G, Baker JV, Lévy Y, Davey RT Jr, Phillips AN, Neaton JD, Lundgren JD, Deeks SG; INSIGHT SILCAAT Scientific Committee.

AIDS. 2014 Jul 31;28(12):1791-6. doi: 10.1097/QAD.0000000000000344.

38.

Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.

Cortez KJ, Proschan MA, Barrett L, Brust DG, Weatherley B, Formentini E, Davey RT, Masur H, Polis MA, Neumann And AU, Kottilil S.

HIV Clin Trials. 2013 Jul-Aug;14(4):149-59. doi: 10.1310/hct1404-149.

39.

HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Maldarelli F, Kearney M, Palmer S, Stephens R, Mican J, Polis MA, Davey RT, Kovacs J, Shao W, Rock-Kress D, Metcalf JA, Rehm C, Greer SE, Lucey DL, Danley K, Alter H, Mellors JW, Coffin JM.

J Virol. 2013 Sep;87(18):10313-23. doi: 10.1128/JVI.01225-12. Epub 2013 May 15.

40.

The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.

Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups.

PLoS One. 2013;8(2):e57121. doi: 10.1371/journal.pone.0057121. Epub 2013 Feb 27.

41.

Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.

Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, Kottilil S, Kohli A.

AIDS Res Hum Retroviruses. 2013 Apr;29(4):665-72. doi: 10.1089/AID.2012.0320. Epub 2013 Feb 11.

42.

Recurrent Meningitis and Subarachnoid Hemorrhage Due to Salmonella in an HIV+ Patient: Case Report and Mini-Review of the Literature.

Belloso WH, Romano M, Greco GS, Davey RT, Perelsztein AG, Sánchez ML, Ajzenszlos MR, Otegui IM.

Open AIDS J. 2011;5:62-6. doi: 10.2174/1874613601105010062. Epub 2011 Jul 11.

43.

The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.

Read SW, Ciccone EJ, Mannon PJ, Yao MD, Chairez CL, Davey RT, Kovacs JA, Sereti I.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):340-3. doi: 10.1097/QAI.0b013e31820bf84c.

44.

Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.

Lifson AR; INSIGHT Endpoint Review Committee Writing Group, Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson JH, Worley J, INSIGHT Study Group.

HIV Clin Trials. 2010 Jul-Aug;11(4):205-19. doi: 10.1310/hct1104-205.

45.

A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.

Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, Ssali F, Dewar R, Daucher M, Davey RT Jr, Mugyenyi P, Fauci AS, Quinn TC, Dybul MR.

PLoS One. 2010 Apr 22;5(4):e10307. doi: 10.1371/journal.pone.0010307.

46.

Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.

Moss RB, Davey RT, Steigbigel RT, Fang F.

J Antimicrob Chemother. 2010 Jun;65(6):1086-93. doi: 10.1093/jac/dkq100. Epub 2010 Apr 7. Review.

PMID:
20375034
47.

Interferon-alpha produces significant decreases in HIV load.

Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC.

J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090.

48.

Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT Jr, Connors M.

J Virol. 2009 Nov;83(22):11876-89. doi: 10.1128/JVI.01153-09. Epub 2009 Sep 2.

49.

Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents.

Jahrling P, Rodak C, Bray M, Davey RT.

Biosecur Bioterror. 2009 Jun;7(2):135-43. doi: 10.1089/bsp.2009.0002.

50.

Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.

Porter BO, Shen J, Kovacs JA, Davey RT, Rehm C, Lozier J, Csako G, Nghiem K, Costello R, Lane HC, Sereti I.

AIDS. 2009 Sep 24;23(15):2015-9. doi: 10.1097/QAD.0b013e32832d72c6.

Supplemental Content

Loading ...
Support Center